Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
基本信息
- 批准号:8090583
- 负责人:
- 金额:$ 56.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2016-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): During treatment recurrent cancers build up multidrug resistance to conventional and novel chemotherapeutic agents representing a formidable challenge in clinical cancer therapy, especially for the effective treatment of gynecological malignancies. This R01 proposal describes a targeted-, combination imaging agent and therapeutic nanoemulsion, designated NMI-500, designed to provide timely diagnostic information on where the co-deliver treatment is accumulating and provide clinicians the quantitative insight to adjust treatment schedules in light of this new information. A team of investigators from two commercial and two academic organizations will collaborate to develop this clinically translatable strategy, initially addressing recurrent multidrug resistant phenotype. NMI-500 uses folate to specifically target docetaxel (DTX), and gadolinium (Gd) an MR imaging agent to localized disease as well as distal metastases. NMI-500's targeting moiety folate is known to improve uptake by tumors expressing folate receptor alpha (FR-a). FR- a, largely absent from normal tissue, has been shown to be over expressed on >80% of recurring ovarian tumors. In breast cancer high FR-an expression has been linked to poor clinical outcomes. The imaging component of NMI-500 will be achieved with the MRI contrast agent Gd, which has been shown to enhance contrast efficiency when conjugated to a nanoemulsion.1 Specific aims will assess and validate the imaging, targeting, efficacy and pharmacokinetics of the combination imaging/chemotherapeutic product, NMI-500.
PUBLIC HEALTH RELEVANCE: As stated in the PAR ".nano-carriers developed for one or more imaging systems for the purposes that include transport of therapeutic agents, adds complexity to their design, optimization and validation". Our proposal challenges the paradigm that such complexity cannot be overcome to complete the cycle of innovation by translating basic science into clinical strategies to detect in real-time the accumulation of therapy at the primary and distal metastasises. We strongly believe complex combination modalities like NMI-500 will be part of the personalized medicine revolution that is only now beginning and its first target should be the dismal mortality rates associated with ovarian cancer. During treatment recurrent cancers build up multidrug resistance to conventional and novel chemotherapeutic agents representing a formidable challenge in clinical cancer therapy, especially for the effective treatment of gynecological malignancies. This R01 proposal describes a targeted-, combination imaging agent and therapeutic nanoemulsion, designated NMI-500, designed to provide timely diagnostic information on where the co-deliver treatment is accumulating and provide clinicians the quantitative insight to adjust treatment schedules in light of this new information. A team of investigators from two academic and two commercial organizations will collaborate to develop this clinically translatable strategy, initially addressing recurrent multidrug resistant phenotype. NMI-500 uses folate to specifically target docetaxel (DTX), and gadolinium (Gd) an MR imaging agent to localized disease as well as distal metastases. NMI-500's targeting moiety folate is known to improve uptake by tumors expressing folate receptor alpha (FR-a). FR- a, largely absent from normal tissue, has been shown to be over expressed on >80% of recurring ovarian tumors. In breast cancer high FR-an expression has been linked to poor clinical outcomes. The imaging component of NMI-500 will be achieved with the MRI contrast agent Gd, which has been shown to enhance contrast efficiency when conjugated to a nanoemulsion.1 Specific aims will assess and validate the imaging, targeting, efficacy and pharmacokinetics of the combination imaging/chemotherapeutic product, NMI-500.
描述(由申请人提供):在治疗期间,复发性癌症在临床癌症治疗中代表了巨大挑战的传统和新型化学治疗剂的多药耐药性,尤其是为了有效治疗妇科恶性肿瘤。该R01提案描述了指定为NMI-500的靶向组合成像剂和治疗性纳米乳液,旨在提供及时的诊断信息,以介绍共同服务器的累积何处,并为临床医生提供定量洞察力,以根据这些新信息来调整治疗时间表。来自两个商业和两个学术组织的一个调查人员团队将合作制定这种临床上可翻译的策略,最初解决反复的多药耐药表型。 NMI-500使用叶酸特异性靶向多西他赛(DTX),而Gadolinium(GD)是局部疾病和远端转移的MR成像剂。已知NMI-500的靶向部分叶酸可以通过表达叶酸受体α(FR-A)的肿瘤改善摄取。 Fr- A,很大程度上没有正常组织,已证明在> 80%的复发性卵巢肿瘤上表达过度。在乳腺癌中,高fr-An表达与临床结果不佳有关。 NMI-500的成像成分将通过MRI对比剂GD实现,在与纳米乳液结合时已证明可以提高对比度的效率。1具体目标将评估和验证组合成像/化学成像/化学型产品的成像,靶向,靶向,功效和药代动力学,NMI-I-500。
公共卫生相关性:如“ PAR”中所述的。为一种或多种成像系统开发的用于包括治疗剂的运输的目的,为其设计,优化和验证增添了复杂性。”我们的提议挑战了这种范式,即通过将基础科学转化为临床策略来检测到实时和远端转移的治疗积累,无法克服这种复杂性来完成创新的周期。我们坚信,像NMI-500这样的复杂组合方式将成为个性化医学革命的一部分,该革命目前才开始,其第一个目标应该是与卵巢癌相关的令人沮丧的死亡率。 在治疗过程中,复发性癌症会产生对常规和新型化学治疗剂的多药耐药性,代表了临床癌症治疗中的巨大挑战,尤其是在有效治疗妇科恶性肿瘤方面。该R01提案描述了指定为NMI-500的靶向组合成像剂和治疗性纳米乳液,旨在提供及时的诊断信息,以介绍共同服务器的累积何处,并为临床医生提供定量洞察力,以根据这些新信息来调整治疗时间表。来自两个学术和两个商业组织的一个调查人员团队将合作制定这种临床上可翻译的策略,最初针对反复的多药耐药表型。 NMI-500使用叶酸特异性靶向多西他赛(DTX),而Gadolinium(GD)是局部疾病和远端转移的MR成像剂。已知NMI-500的靶向部分叶酸可以通过表达叶酸受体α(FR-A)的肿瘤改善摄取。 Fr- A,很大程度上没有正常组织,已证明在> 80%的复发性卵巢肿瘤上表达过度。在乳腺癌中,高fr-An表达与临床结果不佳有关。 NMI-500的成像成分将通过MRI对比剂GD实现,在与纳米乳液结合时已证明可以提高对比度的效率。1具体目标将评估和验证组合成像/化学成像/化学型产品的成像,靶向,靶向,功效和药代动力学,NMI-I-500。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Mansoor M Amiji的其他基金
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
TGX-1214 - 治疗晚期胰腺癌的联合策略
- 批准号:1060797110607971
- 财政年份:2023
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Intranasal gene delivery for Alzheimer’s disease
鼻内基因递送治疗阿尔茨海默病
- 批准号:1030827710308277
- 财政年份:2021
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
用 MicroRNA 纳米载体重编程 PDAC 中的肿瘤相关巨噬细胞
- 批准号:95177849517784
- 财政年份:2017
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Integrated Nano-Therapeutics to Overcome Tumor Plasticity and Resistance
综合纳米疗法克服肿瘤可塑性和耐药性
- 批准号:91652279165227
- 财政年份:2017
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
用 MicroRNA 纳米载体重编程 PDAC 中的肿瘤相关巨噬细胞
- 批准号:93820149382014
- 财政年份:2017
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Oral Gene Delivery to Improve Iron Overload Disorders
口服基因递送改善铁过载疾病
- 批准号:91731169173116
- 财政年份:2016
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Targeted Platinates/siRNA Combination Therapy for Resistant Lung Cancer
靶向铂酸盐/siRNA 联合治疗耐药肺癌
- 批准号:86885588688558
- 财政年份:2014
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
- 批准号:82487988248798
- 财政年份:2011
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
- 批准号:86334308633430
- 财政年份:2011
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
- 批准号:84507878450787
- 财政年份:2011
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
相似国自然基金
基因与家庭不利环境影响儿童反社会行为的表观遗传机制:一项追踪研究
- 批准号:
- 批准年份:2020
- 资助金额:58 万元
- 项目类别:面上项目
不利地质结构对地下洞室群围岩地震响应影响研究
- 批准号:51009131
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
列车制动力对铁路桥梁的作用机理及最不利影响的研究
- 批准号:50178004
- 批准年份:2001
- 资助金额:23.0 万元
- 项目类别:面上项目
相似海外基金
The Role of m6A-RNA Methylation in Memory Formation and Recall and Its Modulation and Influence on Long-Term Outcomes as a Consequence of Early Life Lead Exposure
m6A-RNA 甲基化在记忆形成和回忆中的作用及其对早期铅暴露对长期结果的影响
- 批准号:1065802010658020
- 财政年份:2023
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Mechanisms underlying age-based stereotype threat effects
基于年龄的刻板印象威胁效应的潜在机制
- 批准号:1072759310727593
- 财政年份:2023
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
A Phase II Randomized Placebo Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Physical Frailty and Tumor Necrosis Factor-alpha and Associated Immune Markers in Older Cancer Survivors
表没食子儿茶素-3-没食子酸酯 (EGCG) 对老年癌症幸存者身体虚弱和肿瘤坏死因子-α 及相关免疫标志物的 II 期随机安慰剂对照试验
- 批准号:1057043810570438
- 财政年份:2023
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Food and Non-Food Self-Regulation in Children's Obesity Risk: A Biopsychosocial Perspective
儿童肥胖风险中的食品和非食品自我调节:生物心理社会视角
- 批准号:1056181010561810
- 财政年份:2023
- 资助金额:$ 56.88万$ 56.88万
- 项目类别:
Improving Information Sharing Between Family Caregivers and Home Care Aides Caring for Persons Living with ADRD
改善照顾 ADRD 患者的家庭护理人员和家庭护理助理之间的信息共享
- 批准号:1057114410571144
- 财政年份:2023
- 资助金额:$ 56.88万$ 56.88万
- 项目类别: